Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BGB-A3055
i
Other names:
BGB-A3055
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BeiGene
Drug class:
CCR8 inhibitor
Related drugs:
‹
FPA157 (1)
ABBV-514 (0)
CHS-114 (0)
GS-1811 (0)
HBM1022 (0)
IPG7236 (0)
LM-108 (0)
S-531011 (0)
ZL-1218 (0)
FPA157 (1)
ABBV-514 (0)
CHS-114 (0)
GS-1811 (0)
HBM1022 (0)
IPG7236 (0)
LM-108 (0)
S-531011 (0)
ZL-1218 (0)
›
Associations
News
Trials
Filter by
Latest
5ms
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=318, Recruiting, BeiGene
5 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
Tevimbra (tislelizumab) • BGB-A3055
7ms
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=318, Recruiting, BeiGene | Phase classification: P1a/1b --> P1
7 months ago
Phase classification • Combination therapy • Metastases
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
Tevimbra (tislelizumab) • BGB-A3055
9ms
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1a/1b, N=318, Recruiting, BeiGene | Not yet recruiting --> Recruiting
9 months ago
Enrollment open • Combination therapy • IO biomarker • Metastases
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
PD-L1 expression • CCR8 expression
|
Tevimbra (tislelizumab) • BGB-A3055
11ms
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1a/1b, N=318, Not yet recruiting, BeiGene
11 months ago
New P1 trial • Combination therapy • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CCR8 (C-C Motif Chemokine Receptor 8)
|
PD-L1 expression • CCR8 expression
|
Tevimbra (tislelizumab) • BGB-A3055
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login